Search results
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
CNBC· 6 days agoSkyrocketing demand for a class of weight loss and diabetes treatments has lifted Eli Lilly to new...
Gateway - Quartz
Quartz· 5 days agoCenters for Medicare and Medicaid Services (CMS) announced on Thursday. “CMS has issued guidance to Medicare Part D plans stating that ...
Gateway - Quartz
Quartz· 6 days agoAfter dominating the market for weight loss drugs, Ozempic maker Novo Nordisk has set its sights on tackling treatments for heart disease next. Cardior, a Germany-based drug maker, develops ...
Letter: We need alternatives to opioids
Bangor Daily News· 3 days agoAs a retired millworker, I have witnessed the devastating impact of the opioid crisis on mill towns throughout Maine and communities around the entire...
Gateway - Quartz
Quartz· 6 days agoNovo Nordisk, the maker of the mega-popular diabetes and weight loss medications Ozempic and Wegovy, is set to report its first quarter earnings on May 2. The Danish pharma giant is one-half ...
US Drug Negotiations Plan Shifts Focus for Rare Disease Programs
Bloomberg Law· 7 days agoThe rare disease community is pushing for changes in the Inflation Reduction Act’s drug price-setting scheme as it leads more drugmakers and investors to reconsider development of drugs to treat ...